- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | StemRIM's Shionogi-Partnered Stroke Drug Misses Its Primary Endpoint While a Rare-Disease Trial Delivers | - | Tokyo Brief | ||
| 05.08. | Shionogi CEO says firm is pursuing acquisitions and mulling expanded U.S. production | 3 | Japan Times | ||
| 03.08. | Shionogi & Co. GAAP EPS of ¥114.78, revenue of ¥163.31B; reaffirms FY 2027 outlook | 5 | Seeking Alpha | ||
| SHIONOGI & CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 03.08. | Shionogi & Co., Ltd. Bottom Line Advances In Q1 | 347 | AFX News | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) announced a profit for its first quarter that Increased, from the same period last yearThe company's bottom line came in at JPY97.696 billion,... ► Artikel lesen | |
| 20.07. | Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth | 4 | Zacks | ||
| 15.06. | UBS stuft Shionogi-Aktie hoch: Günstige Bewertung und Pipeline als Kaufargumente | 8 | Investing.com Deutsch | ||
| 01.06. | Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative | 6 | FiercePharma | ||
| 12.05. | Shionogi & Co., Ltd. Profit Climbs In Full Year | 490 | AFX News | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) revealed earnings for its full year that Increased, from last yearThe company's bottom line totaled JPY205.159 billion, or JPY241.04 per share.... ► Artikel lesen | |
| 21.04. | Shionogi starts phase 2 clinical trial for Pompe Disease | 6 | PMLiVE | ||
| 09.04. | Shionogi secures $482m BARDA contract to tackle AMR crisis | 3 | Pharmaceutical Technology | ||
| 08.04. | Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant | 3 | FiercePharma | ||
| 07.04. | Shionogi USA: ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja/Fetcroja (cefiderocol) in MBL-Producing Enterobacterales Infections | 544 | Business Wire | Real-world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day 28, for patients infected with highly resistant metallo-beta lactamase... ► Artikel lesen | |
| 03.04. | Shionogi: $2.5 Billion Acquisition Of RADICAVA Establishes Rare Disease Platform | 9 | pulse2.com | ||
| 01.04. | ViiV Healthcare: Pfizer steigt aus, Shionogi erhöht Anteil | 27 | Investing.com Deutsch | ||
| 01.04. | Shionogi completes purchase of Pfizer stake in GSK's ViiV Healthcare | 9 | Alliance News | ||
| 24.03. | Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream | 2 | FierceBiotech | ||
| 10.02. | Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd. | 640 | PR Newswire | BELFAST, Northern Ireland, Feb. 10, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and... ► Artikel lesen | |
| 30.01. | Shionogi & Co., Ltd. Reports Rise In Nine Months Profit | 595 | AFX News | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) reported earnings for its nine months that Increased, from last yearThe company's bottom line came in at JPY158.225 billion, or JPY185.91 per share.... ► Artikel lesen | |
| 30.10.25 | Shionogi Announces Corporate Reorganization Following Japan Tobacco Pharma Merger | 1.237 | AFX News | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. Thursday announced it will implement a corporate reorganization and several personnel reassignments, effective December 1, 2025, in line with the upcoming... ► Artikel lesen | |
| 27.10.25 | Shionogi & Co. H1 Net Profit Rises, But Revenue Slips; Revises Annual Outlook | 781 | AFX News | TOKYO (dpa-AFX) - Shionogi & Company Limited (SGIOF, 4507.T), a Japanese pharmaceutical company, on Monday reported a rise in net profit for the first half, helped by an increase in finance... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 9,602 | -1,60 % | XFRA NEW INSTRUMENTS AVAILABLE ON 19.08.2026 | The following instruments on XETRA do have their first trading 19.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 19.08.2026
Aktien
1 US6420451089 Atlas Energy Solutions... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 295,40 | -1,04 % | West Pharmaceutical Services hebt Wachstumsausblick auf Wells-Fargo-Konferenz an | ||
| SHIONOGI | 15,810 | -1,43 % | StemRIM's Shionogi-Partnered Stroke Drug Misses Its Primary Endpoint While a Rare-Disease Trial Delivers | ||
| KALA BIO | 0,578 | +1,03 % | KALA BIO, Inc. - 8-K, Current Report | ||
| CHARLOTTES WEB | 0,266 | -1,48 % | Charlotte's Web Holdings, Inc.: Charlotte's Web and Edibles.com Team up to Protect Consumer Access and Shape Hemp's Future | Louisville, Colorado--(Newsfile Corp. - August 25, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF), a market leader in hemp wellness, and Edibles.com, a premier retailer and online... ► Artikel lesen | |
| MIRUM PHARMACEUTICALS | 89,82 | +5,97 % | Mirum Pharmaceuticals, Inc. - 8-K, Current Report | ||
| BEXIMCO PHARMACEUTICALS | 0,625 | 0,00 % | AIM - Restoration - Beximco Pharmaceuticals PLC | ||
| LUYE PHARMA | 0,196 | -0,51 % | LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT MRNA VACCINE LY01620 FOR THE TREATMENT OF CERVICAL PRECANCEROUS LESIONS AND HPV-RELATED TUMORS TO ENTER INTO ... | ||
| PERCHERON THERAPEUTICS | 0,003 | 0,00 % | PERCHERON THERAPEUTICS LIMITED: Notice under S708A | ||
| AVANT BRANDS | 0,340 | -9,09 % | Avant Brands Inc.: Avant Brands Completes EU GMP Audit at Flowr Facility | KELOWNA, BC / ACCESS Newswire / August 20, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU) ("Avant" or the "Company"), is pleased to announce the completion of its European Union Good Manufacturing... ► Artikel lesen | |
| AYURCANN | 0,001 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.07.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 02.07.2026
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.07.2026
ISIN Name
CA05476A1012... ► Artikel lesen | |
| KALBE FARMA | 0,029 | -5,00 % | Profit under pressure, KLBF weighs price hikes and Enseval delisting: Kalbe Farma is opting for a defensive strategy ... | ||
| EVEREST MEDICINES | 2,900 | -2,03 % | EVEREST MED (01952): CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT | ||
| KOBAYASHI PHARMACEUTICAL | 31,200 | 0,00 % | Oasis Raises Kobayashi Pharmaceutical Stake to 14.4%, Reserves Right to Push for Board Ouster | ||
| BAYER | 48,170 | -1,09 % | Nicht nur Bayer verdient am Weltmarkt mit, ohne überall selbst präsent zu sein: Ein australischer Psychedelika-Anbieter setzt auf dasselbe Grundprinzip |
Das Unternehmen SHIONOGI & CO LTD ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 7,850 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHIONOGI & CO LTD ADR finden Sie auf Wallstreet Online.